Status:
UNKNOWN
Efficiency of the Hepatitis B Sci-B-Vac Vaccine in HIV Positive Patients
Lead Sponsor:
Tel-Aviv Sourasky Medical Center
Collaborating Sponsors:
SciGen, Israel
Conditions:
HIV
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
HBV vaccination is of paramount importance among HIV positive persons due to an increased risk of infection and disease progression. The most widely used ENGERIX B vaccine reaches a lower rate of vacc...
Detailed Description
A cohort of 100 HIV positive, HBV negative individuals who have not been vaccinated against HBV before will be prospectively given 3 doses of Sci-B-Vac at 0, 1 and 6 months. HBV antibodies will be che...
Eligibility Criteria
Inclusion
- HBV negative
- HIV positive individuals
- Above the age of 18
- Treated at the TASMC Aids clinic, who have signed and informed consent and have never been vaccinated against HBV before
Exclusion
- Pregnant women
- HBV positivity
- Previous HBV vaccination
Key Trial Info
Start Date :
November 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2013
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT01437475
Start Date
November 1 2011
End Date
November 1 2013
Last Update
October 6 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dan Turner
Tel Aviv, Israel, 64239